
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9591073/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prefrontal and striatal dopamine D2/D3 receptors correlate with fMRI BOLD activation during stopping. Brain Imaging and Behavior, 2022, 16, 186-198.	1.1	7
2	Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports, 2022, 9, 48-58.	1.6	7
3	The negative impact of vitamin D on antipsychotic drug exposure may counteract its potential benefits in schizophrenia. British Journal of Clinical Pharmacology, 2022, 88, 3193-3200.	1.1	6
4	Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. , 2022, 1, 100104.		12
5	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Frontiers in Psychiatry, 2022, 13, 826138.	1.3	8
6	Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice. Frontiers in Psychiatry, 2022, 13, 832209.	1.3	10
7	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. Lancet Psychiatry,the, 2022, 9, 291-306.	3.7	6
8	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
9	Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. Expert Review of Clinical Pharmacology, 2022, 15, 243-249.	1.3	2
10	Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis. Pharmacopsychiatry, 2022, , .	1.7	0
11	Ketamine Metabolite Plasma Levels as Potential Blood Markers of Ketamine Efficacy in Treatment Resistant Depression. Pharmacopsychiatry, 2022, , .	1.7	Ο
12	Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. Pharmacopsychiatry, 2022, , .	1.7	0
13	How valid are therapeutic reference ranges for psychotropic drugs?. Pharmacopsychiatry, 2022, , .	1.7	0
14	The therapeutic reference range for olanzapine revised $\hat{a} \in$ '' how to combine old and new findings. Pharmacopsychiatry, 2022, , .	1.7	0
15	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. Pharmacopsychiatry, 2022, , .	1.7	0
16	Case series: Higher antipsychotic drug levels in patients with schizophrenia after COVID-19 vaccination. Pharmacopsychiatry, 2022, , .	1.7	0
17	Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia. Psychiatric Quarterly, 2021, 92, 177-191.	1.1	2
18	Molecular imaging of schizophrenia: Neurochemical findings in a heterogeneous and evolving disorder. Behavioural Brain Research, 2021, 398, 113004.	1.2	23

#	Article	IF	CITATIONS
19	Treatment Goals for Patients with Schizophrenia — A Narrative Review of Physician and Patient Perspectives. Pharmacopsychiatry, 2021, 54, 53-59.	1.7	4
20	Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. Pharmacopsychiatry, 2021, 54, 31-35.	1.7	5
21	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. Therapeutic Drug Monitoring, 2021, 43, 79-102.	1.0	23
22	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. Journal of Psychopharmacology, 2021, 35, 273-278.	2.0	13
23	Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1437-1443.	1.8	4
24	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) Tj ETQq0 0 0 Psychiatry, 2021, 22, 561-628.	rgBT /Ove 1.3	erlock 10 Tf 50 17
25	The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry, 2021, 54, 191-199.	1.7	12
26	Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. Clinical Pharmacokinetics, 2021, 60, 1583-1589.	1.6	1
27	Psychedelics: A New Treatment Paradigm in Psychiatry?. Pharmacopsychiatry, 2021, 54, 149-150.	1.7	6
28	Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?. Journal of Neurochemistry, 2021, 156, 560-562.	2.1	5
29	Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews. Frontiers in Psychiatry, 2021, 12, 787043.	1.3	17
30	P.0693 Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. European Neuropsychopharmacology, 2021, 53, S507-S508.	0.3	0
31	P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – study design, rationale and current status. European Neuropsychopharmacology, 2021, 53, S306.	0.3	0
32	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 83-94.	1.8	4
33	The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. Pharmacopsychiatry, 2020, 53, 65-70.	1.7	2
34	Changes in Clozapine Bioavailability in a Percutaneous Endoscopic Gastrostomy-Fed Patient With Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2020, 40, 306-308.	0.7	4
35	Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance. Frontiers in Psychiatry, 2020, 11, 5.	1.3	84
36	Pregnancy exposure to venlafaxine—Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. Journal of Affective Disorders, 2020, 266, 578-584.	2.0	10

#	Article	IF	CITATIONS
37	Pharmacokinetic interactions between clozapine and sertraline in smokers and nonâ€smokers. Basic and Clinical Pharmacology and Toxicology, 2020, 127, 303-308.	1.2	8
38	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	1.1	86
39	10 How valid are therapeutic reference ranges for psychotropic drugs?. , 2020, 53, .		0
40	Antidepressants in breast milk; comparative analysis of excretion ratios. Archives of Women's Mental Health, 2019, 22, 383-390.	1.2	22
41	The downside of downregulation. Brain, 2019, 142, 1500-1502.	3.7	3
42	Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophrenia Research, 2019, 210, 143-148.	1.1	29
43	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. European Journal of Clinical Pharmacology, 2019, 75, 1109-1116.	0.8	8
44	Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomized NeSSy trial. European Neuropsychopharmacology, 2019, 29, 720-739.	0.3	29
45	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 851-857.	1.8	5
46	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. International Clinical Psychopharmacology, 2019, 34, 241-246.	0.9	8
47	Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 550-560.	0.7	10
48	Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. Neuroscience and Biobehavioral Reviews, 2019, 106, 141-164.	2.9	32
49	Comprehensive Measurements of Intrauterine and Postnatal Exposure to Lamotrigine. Clinical Pharmacokinetics, 2019, 58, 535-543.	1.6	20
50	Peripheral Oxytocin Predicts Higher-Level Social Cognition in Men Regardless of Empathy Quotient. Pharmacopsychiatry, 2019, 52, 148-154.	1.7	5
51	Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophrenia Bulletin, 2019, 45, 350-359.	2.3	28
52	Influence of Kidney Function on Serum Risperidone Concentrations in Patients Treated With Risperidone. Journal of Clinical Psychiatry, 2019, 80, .	1.1	10
53	The clinical relevance of the pharmacological interaction between clozapine and sertraline. , 2019, 52, .		0
54	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World Journal of Biological Psychiatry, 2018, 19, 162-174.	1.3	103

#	Article	IF	CITATIONS
55	The role of striatal dopamine D2/3 receptors in cognitive performance in drug-free patients with schizophrenia. Psychopharmacology, 2018, 235, 2221-2232.	1.5	16
56	Reduced clearance of venlafaxine in a combined treatment with quetiapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 85, 116-121.	2.5	18
57	Pregnancy exposure to quetiapine – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. Schizophrenia Research, 2018, 195, 252-257.	1.1	15
58	Editorial to Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology. Pharmacopsychiatry, 2018, 51, 5-6.	1.7	18
59	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018, 51, 9-62.	1.7	787
60	Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. Clinical Pharmacokinetics, 2018, 57, 729-737.	1.6	14
61	Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. Journal of Affective Disorders, 2018, 227, 506-511.	2.0	16
62	Pharmacokinetics of risperidone in different application forms – Comparing long-acting injectable and oral formulations. European Neuropsychopharmacology, 2018, 28, 130-137.	0.3	22
63	Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1125-1138.	1.0	4
64	Sex and body weight are major determinants of venlafaxine pharmacokinetics. International Clinical Psychopharmacology, 2018, 33, 322-329.	0.9	12
65	How to Treat Hypertension in Venlafaxine-Medicated Patients—Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. Journal of Clinical Psychopharmacology, 2018, 38, 498-501.	0.7	9
66	Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients. Journal of Clinical Psychiatry, 2018, 79, .	1.1	16
67	Comprehensive measurements of intrauterine and postnatal exposure to lamotrigine. , 2018, 51, .		0
68	The effect of pharmacological interaction between a proton pump inhibitor pantoprazole and clozapine. Pharmacopsychiatry, 2018, 51, .	1.7	0
69	Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Journal of Affective Disorders, 2017, 212, 1-6.	2.0	31
70	Cytochrome P450â€mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. British Journal of Clinical Pharmacology, 2017, 83, 1668-1675.	1.1	11
71	Naming for Psychotropic Drugs: Dilemma and Challenge. Pharmacopsychiatry, 2017, 50, 1-2.	1.7	17
72	Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 101-106.	2.5	7

#	Article	IF	CITATIONS
73	Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. Schizophrenia Research, 2017, 185, 51-57.	1.1	21
74	Comparison of Clomethiazole and Diazepam in the Treatment of Alcohol Withdrawal Syndrome in Clinical Practice. European Addiction Research, 2017, 23, 211-218.	1.3	20
75	Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1059-1060.	1.3	4
76	Pregnancy exposure to citalopram – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 213-219.	2.5	22
77	Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system. Addiction Biology, 2017, 22, 1449-1458.	1.4	7
78	Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 325-333.	1.8	13
79	Effects of alexithymia and empathy on the neural processing of social and monetary rewards. Brain Structure and Function, 2017, 222, 2235-2250.	1.2	25
80	Association of Common Polymorphisms in the Nicotinic Acetylcholine Receptor Alpha4 Subunit Gene with an Electrophysiological Endophenotype in a Large Population-Based Sample. PLoS ONE, 2016, 11, e0152984.	1.1	9
81	Measuring citalopram in blood and central nervous system. International Clinical Psychopharmacology, 2016, 31, 119-126.	0.9	12
82	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. European Journal of Clinical Pharmacology, 2016, 72, 1091-1098.	0.8	25
83	Risperidone-induced extrapyramidal side effects. International Clinical Psychopharmacology, 2016, 31, 259-264.	0.9	20
84	Pharmacokinetic Interaction Between Valproic Acid, Meropenem, and Risperidone. Journal of Clinical Psychopharmacology, 2016, 36, 90-92.	0.7	10
85	Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study. Clinical Trials, 2016, 13, 251-259.	0.7	6
86	Neural correlates of naturalistic social cognition: brain-behavior relationships in healthy adults. Social Cognitive and Affective Neuroscience, 2016, 11, 1741-1751.	1.5	30
87	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. Psychoneuroendocrinology, 2016, 73, 9-15.	1.3	31
88	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. Journal of Clinical Psychopharmacology, 2016, 36, 554-561.	0.7	28
89	Interaction Between Risperidone, Venlafaxine, and Metronidazole. Journal of Clinical Psychopharmacology, 2016, 36, 730-733.	0.7	7
90	Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry,the, 2016, 3, 717-729.	3.7	56

#	Article	IF	CITATIONS
91	Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients – thinking of clinically relevant CYP2D6 interactions. Journal of Psychopharmacology, 2016, 30, 803-809.	2.0	19
92	Response from the authors. Clinical Trials, 2016, 13, 262-263.	0.7	0
93	Replication of the association between CHRNA4 rs1044396 and harm avoidance in a large population-based sample. European Neuropsychopharmacology, 2016, 26, 150-155.	0.3	6
94	Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers. Biological Psychiatry, 2016, 80, 198-206.	0.7	40
95	Duloxetine enters the brain – But why is it not found in the cerebrospinal fluid. Journal of Affective Disorders, 2016, 189, 159-163.	2.0	8
96	Lamotrigine in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. International Clinical Psychopharmacology, 2015, 30, 249-254.	0.9	9
97	Suicide Attempt During Late Pregnancy With Quetiapine. Journal of Clinical Psychopharmacology, 2015, 35, 343-344.	0.7	10
98	Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. Psychopharmacology, 2015, 232, 1607-1617.	1.5	17
99	Distribution pattern of mirtazapine and normirtazapine in blood and CSF. Psychopharmacology, 2015, 232, 807-813.	1.5	9
100	Impact of personal economic environment and personality factors on individual financial decision making. Frontiers in Psychology, 2014, 5, 158.	1.1	12
101	Effects of psychotropic drugs on brain plasticity in humans. Restorative Neurology and Neuroscience, 2014, 32, 163-181.	0.4	9
102	Differential patterns of nucleus accumbens activation during anticipation of monetary and social reward in young and older adults. Social Cognitive and Affective Neuroscience, 2014, 9, 825-831.	1.5	92
103	Impaired sleep quality and sleep duration in smokers—results from the <scp>G</scp> erman <scp>M</scp> ulticenter <scp>S</scp> tudy on <scp>N</scp> icotine <scp>D</scp> ependence. Addiction Biology, 2014, 19, 486-496.	1.4	116
104	Neural evidence for an association between social proficiency and sensitivity to social reward. Social Cognitive and Affective Neuroscience, 2014, 9, 661-670.	1.5	29
105	Acute and Sustained Effects of Methylphenidate on Cognition and Presynaptic Dopamine Metabolism: An [ <sup>18</sup> F]FDOPA PET Study. Journal of Neuroscience, 2014, 34, 14769-14776.	1.7	24
106	Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies. Neuropharmacology, 2014, 84, 152-158.	2.0	13
107	Plasma Levels and Cerebrospinal Fluid Penetration of Venlafaxine in a Patient With a Nonfatal Overdose During a Suicide Attempt. Journal of Clinical Psychopharmacology, 2014, 34, 398-399.	0.7	2
108	Oxytocin Influences Processing of Socially Relevant Cues in the Ventral Tegmental Area of the Human Brain. Biological Psychiatry, 2013, 74, 172-179.	0.7	205

#	Article	IF	CITATIONS
109	Neuropsychological Correlates of Transcription Factor AP-2Beta, and Its Interaction with COMT and MAOA in Healthy Females. Neuropsychobiology, 2013, 68, 79-90.	0.9	6
110	Cariprazine, a new, orally active dopamine D <sub>2/3</sub> receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Review of Neurotherapeutics, 2013, 13, 1141-1159.	1.4	63
111	Effects of antipsychotic treatment on cognition in healthy subjects. Journal of Psychopharmacology, 2013, 27, 374-385.	2.0	27
112	The role of 5-HT in response inhibition and re-engagement. European Neuropsychopharmacology, 2013, 23, 830-841.	0.3	16
113	Functional Polymorphism in the Neuropeptide Y Gene Promoter (rs16147) Is Associated with Serum Leptin Levels and Waist-Hip Ratio in Women. Annals of Nutrition and Metabolism, 2013, 62, 271-276.	1.0	17
114	Neural activation during anticipation of opposite-sex and same-sex faces in heterosexual men and women. Neurolmage, 2013, 66, 223-231.	2.1	23
115	Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. International Journal of Neuropsychopharmacology, 2013, 16, 745-754.	1.0	25
116	The Impact of Dopamine on Aggression: An [ <sup>18</sup> F]-FDOPA PET Study in Healthy Males. Journal of Neuroscience, 2013, 33, 16889-16896.	1.7	51
117	Lack of Association of a Functional Catechol-O-Methyltransferase Gene Polymorphism With Risk of Tobacco Smoking: Results From a Multicenter Case-Control Study. Nicotine and Tobacco Research, 2013, 15, 1322-1327.	1.4	7
118	Surrogate markers for cerebral blood flow correlate with [ <sup>18</sup> F]â€fallypride binding potential at dopamine D <sub>2/3</sub> receptors in human striatum. Synapse, 2013, 67, 199-203.	0.6	21
119	Increased Turnover of Dopamine in Caudate Nucleus of Detoxified Alcoholic Patients. PLoS ONE, 2013, 8, e73903.	1.1	13
120	Schizophrenia risk polymorphisms in the <i>TCF4</i> gene interact with smoking in the modulation of auditory sensory gating. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6271-6276.	3.3	60
121	In Vivo Evidence of Deep Brain Stimulation-Induced Dopaminergic Modulation in Tourette's Syndrome. Biological Psychiatry, 2012, 71, e11-e13.	0.7	40
122	Oxytocin plasma concentrations after single intranasal oxytocin administration – A study in healthy men. Neuropeptides, 2012, 46, 211-215.	0.9	186
123	Genetic Variation in the Neuropeptide Y Gene Promoter Is Associated with Increased Risk of Tobacco Smoking. European Addiction Research, 2012, 18, 246-252.	1.3	16
124	Opiate-Induced Dopamine Release Is Modulated by Severity of Alcohol Dependence: An [18F]Fallypride Positron Emission Tomography Study. Biological Psychiatry, 2011, 70, 770-776.	0.7	34
125	Impact of Different Antidopaminergic Mechanisms on the Dopaminergic Control of Prolactin Secretion. Journal of Clinical Psychopharmacology, 2011, 31, 214-220.	0.7	24
126	P50 sensory gating and smoking in the general population. Addiction Biology, 2011, 16, 485-498.	1.4	24

#	Article	IF	CITATIONS
127	The German multiâ€centre study on smokingâ€related behavior—description of a populationâ€based caseâ€control study. Addiction Biology, 2011, 16, 638-653.	1.4	23
128	The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1958-1966.	2.4	35
129	Dopamine D2/D3 receptor availability and venturesomeness. Psychiatry Research - Neuroimaging, 2011, 193, 80-84.	0.9	11
130	Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. Psychopharmacology, 2011, 218, 733-748.	1.5	15
131	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry, 2011, 44, 195-235.	1.7	774
132	Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging. Pharmacopsychiatry, 2011, 44, 236-248.	1.7	48
133	AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry, 2011, 44, 195-235.	1.7	59
134	Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli. Human Brain Mapping, 2010, 31, 716-726.	1.9	17
135	Serum concentrations of paliperidone versus risperidone and clinical effects. European Journal of Clinical Pharmacology, 2010, 66, 797-803.	0.8	43
136	Serotonergic modulation of response inhibition and reâ€engagement? Results of a study in healthy human volunteers. Human Psychopharmacology, 2010, 25, 472-480.	0.7	20
137	Remission of Drug-Induced Hepatitis After Switching from Risperidone to Paliperidone. American Journal of Psychiatry, 2010, 167, 351-352.	4.0	19
138	Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. International Journal of Neuropsychopharmacology, 2010, 13, 951-960.	1.0	33
139	The P300 event-related potential and smoking — A population-based case–control study. International Journal of Psychophysiology, 2010, 77, 166-175.	0.5	30
140	Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study. Neurobiology of Aging, 2010, 31, 447-463.	1.5	47
141	Dissociation of neural networks for anticipation and consumption of monetary and social rewards. NeuroImage, 2010, 49, 3276-3285.	2.1	273
142	Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. NeuroImage, 2010, 49, 2933-2939.	2.1	28
143	Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Current Opinion in Investigational Drugs, 2010, 11, 823-32.	2.3	17
144	The Role of Imaging in Proof of Concept for CNS Drug Discovery and Development. Neuropsychopharmacology, 2009, 34, 187-203.	2.8	161

#	Article	IF	CITATIONS
145	Anticipation of monetary and social reward differently activates mesolimbic brain structures in men and women. Social Cognitive and Affective Neuroscience, 2009, 4, 158-165.	1.5	336
146	The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nature Reviews Drug Discovery, 2009, 8, 197-202.	21.5	125
147	Bithalamical Deep Brain Stimulation in Tourette Syndrome Is Associated with Reduction in Dopaminergic Transmission. Biological Psychiatry, 2009, 66, e15-e17.	0.7	55
148	Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy. European Psychiatry, 2009, 24, .	0.1	0
149	The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. European Psychiatry, 2009, 24, 143-148.	0.1	17
150	"Absolute―or "relative― Choosing the right outcome measure in neuroimaging. NeuroImage, 2009, 45, 258-259.	2.1	17
151	Reduced serotonin transporter availability in patients with unipolar major depression reflect the level of anxiety. Molecular Psychiatry, 2008, 13, 557-557.	4.1	18
152	Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nature Neuroscience, 2008, 11, 1381-1382.	7.1	150
153	Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Molecular Psychiatry, 2008, 13, 606-613.	4.1	113
154	Baseline [18F]-FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. NeuroImage, 2008, 40, 1222-1231.	2.1	26
155	Enhancement of atomoxetine serum levels by co-administration of paroxetine. International Journal of Neuropsychopharmacology, 2008, 11, 289-91.	1.0	10
156	Association of Low Striatal Dopamine D <sub>2</sub> Receptor Availability With Nicotine Dependence Similar to That Seen With Other Drugs of Abuse. American Journal of Psychiatry, 2008, 165, 507-514.	4.0	189
157	Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [ <sup>18</sup> F]Fallypride PET Study. American Journal of Psychiatry, 2008, 165, 988-995.	4.0	139
158	Striatal D2/D3 Receptor Occupancy, Clinical Response and Side Effects with Amisulpride: An Iodine-123-Iodobenzamide SPET Study. Pharmacopsychiatry, 2008, 41, 169-175.	1.7	46
159	Opioid Receptor PET Reveals the Psychobiologic Correlates of Reward Processing. Journal of Nuclear Medicine, 2008, 49, 1257-1261.	2.8	48
160	Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone. Journal of Clinical Psychopharmacology, 2008, 28, 608-617.	0.7	38
161	Elevated [ <sup>18</sup> F]Fluorodopamine Turnover in Brain of Patients with Schizophrenia: An [ <sup>18</sup> F]Fluorodopa/Positron Emission Tomography Study. Journal of Neuroscience, 2007, 27, 8080-8087.	1.7	149
162	Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. International Journal of Neuropsychopharmacology, 2007, 10, 149.	1.0	16

#	Article	IF	CITATIONS
163	Asymmetry in dopamine D2/3 receptors of caudate nucleus is lost with age. NeuroImage, 2007, 34, 870-878.	2.1	65
164	Brain imaging research: Does the science serve clinical practice?. International Review of Psychiatry, 2007, 19, 541-558.	1.4	33
165	â€`Prefrontal' cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: An exploratory [18F]-fluoro-L-DOPA-PET investigation. Human Brain Mapping, 2007, 28, 931-939.	1.9	71
166	In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D2-like dopamine receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 6819-6829.	1.4	27
167	Altered benzodiazepine receptor sensitivity in alcoholism: A study with fMRI and acute lorazepam challenge. Psychiatry Research - Neuroimaging, 2007, 154, 241-251.	0.9	6
168	Tiagabine does not attenuate alcohol-induced activation of the human reward system. Psychopharmacology, 2007, 191, 975-983.	1.5	12
169	Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. NeuroImage, 2006, 30, 1332-1339.	2.1	71
170	Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. European Neuropsychopharmacology, 2006, 16, 233-240.	0.3	40
171	The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia. Neuropsychopharmacology, 2006, 31, 1027-1035.	2.8	96
172	PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 807-819.	2.4	55
173	Correlation of Alcohol Craving With Striatal Dopamine Synthesis Capacity and D2/3Receptor Availability: A Combined [18F]DOPA and [18F]DMFP PET Study in Detoxified Alcoholic Patients. American Journal of Psychiatry, 2005, 162, 1515-1520.	4.0	253
174	Anterior limbic alpha-like activity: a low resolution electromagnetic tomography study with lorazepam challenge. Clinical Neurophysiology, 2005, 116, 886-894.	0.7	19
175	Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. Journal of Nuclear Medicine, 2005, 46, 964-72.	2.8	61
176	Acute Alcohol Effects on Neuronal and Attentional Processing: Striatal Reward System and Inhibitory Sensory Interactions under Acute Ethanol Challenge. Neuropsychopharmacology, 2004, 29, 1527-1537.	2.8	54
177	The thalamus as the generator and modulator of EEG alpha rhythm: a combined PET/EEG study with lorazepam challenge in humans. NeuroImage, 2004, 22, 637-644.	2.1	160
178	High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. International Journal of Neuropsychopharmacology, 2004, 7, 421-430.	1.0	50
179	Therapeutic Monitoring of New Antipsychotic Drugs. Therapeutic Drug Monitoring, 2004, 26, 156-160.	1.0	105
180	Correlation Between Dopamine D2 Receptors in the Ventral Striatum and Central Processing of Alcohol Cues and Craving. American Journal of Psychiatry, 2004, 161, 1783-1789.	4.0	341

#	Article	IF	CITATIONS
181	Mechanism of New Antipsychotic Medications. Archives of General Psychiatry, 2003, 60, 974.	13.8	200
182	Subchronic Haloperidol Downregulates Dopamine Synthesis Capacity in the Brain of Schizophrenic Patients In Vivo. Neuropsychopharmacology, 2003, 28, 787-794.	2.8	105
183	Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. Journal of Nuclear Medicine, 2003, 44, 109-16.	2.8	37
184	Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels. Neuropsychobiology, 2002, 46, 33-40.	0.9	30
185	Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride. Neuropsychopharmacology, 2002, 27, 248-259.	2.8	261
186	Prolactin secretion is not a core dimension of "atypicality― Psychopharmacology, 2002, 162, 93-93.	1.5	4
187	[ 18 F]Fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1463-1470.	3.3	46
188	Tranylcypromine Abuse Associated With Delirium and Thrombocytopenia. Journal of Clinical Psychopharmacology, 2000, 20, 270-271.	0.7	10
189	Increase in Serum Clomipramine Concentrations Caused by Valproate. Journal of Clinical Psychopharmacology, 2000, 20, 493-494.	0.7	31
190	Occupancy of striatal D 2 -like dopamine receptors after treatment with the sigma ligand EMD 57445, a putative atypical antipsychotic. Psychopharmacology, 1999, 146, 81-86.	1.5	19
191	Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Research, 1999, 89, 275-280.	1.7	19
192	Neuroendocrine response to antipsychotics: effects of drug type and gender. Biological Psychiatry, 1999, 45, 89-97.	0.7	66
193	Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D 2 -like antagonist to a mixed D 1 -/D 2 -like antagonist. Psychopharmacology, 1998, 137, 223-232.	1.5	122
194	Time Course of 5-HT2A Receptor Occupancy in the Human Brain after a Single Oral Dose of the Putative Antipsychotic Drug MDL 100,907 Measured by Positron Emission Tomography. Neuropsychopharmacology, 1997, 17, 175-185.	2.8	56
195	Is There an Advantage to Venlafaxine in Comparison with Other Antidepressants?. Human Psychopharmacology, 1997, 12, 53-64.	0.7	20
196	A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Journal of Psychiatric Research, 1996, 30, 441-451.	1.5	98
197	Subchronic Antidepressant Treatment with Venlafaxine or Imipramine and Effects on Blood Pressure and Heart Rate: Assessment by Automatic 24-Hour Monitoring. Pharmacopsychiatry, 1996, 29, 72-78.	1.7	24
198	The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. Psychopharmacology, 1995, 117, 472-478.	1.5	6

#	ARTICLE	IF	CITATIONS
199	Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology, 1993, 111, 123-126.	1.5	30
200	Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression*. Pharmacopsychiatry, 1992, 25, 254-260.	1.7	42
201	BENZODIAZEPINE-RECEPTORS IN DEPRESSION AND ANXIETY MEASURED BY IOMAZENIL-SPECT. Clinical Neuropharmacology, 1992, 15, 201B.	0.2	1